PRAXIS PRECISION MEDICINES, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $1.43M.
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $4.07M.
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- PRAXIS PRECISION MEDICINES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $2.09M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.43M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $1.43M 10-Q · filed 2026-05-07 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $0.00 derived: sum of 2 quarters · filed 2023-02-07 | $0.00 10-K · filed 2023-02-07 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | ||||
| 2021-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | -$18.00K derived: sum of 2 quarters · filed 2023-02-07 | $4.07M 10-K · filed 2023-02-07 | $4.09M 10-K · filed 2022-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.09M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $4.09M 10-Q · filed 2022-08-08 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $2.09M 10-K · filed 2021-03-17 | |||
| 2019-09-30 | $2.09M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |